| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
64,210,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
141 |
Avg
Vol: |
1,513,129 |
| 52
Week Range: |
$0.000001 - $0.238 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Infinity Pharmaceuticals is a clinical-stage biopharmaceutical company. Co. is focused on advancing eganelisib (IPI-549), an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma. The preclinical findings indicate that eganelisib may have the potential to treat various solid tumors and represents an additive or synergistic approach to restoring anti-tumor immunity in combination with other immunotherapies such as checkpoint inhibitors. Further, preclinical studies showed that eganelisib inhibits the regrowth of tumors that can occur following treatment with chemotherapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
410,196 |
425,190 |
| Total Sell Value |
$0 |
$0 |
$28,714 |
$38,646 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
1 |
2 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Evnin Anthony B |
Director |
– • – |
2012-11-26 |
4 |
A |
$0.00 |
$0 |
I/I |
4,832 |
316,551 |
|
- |
|
| Evnin Anthony B |
Director |
– • – |
2012-11-26 |
4 |
D |
$0.00 |
$0 |
I/I |
(864,565) |
311,719 |
|
- |
|
| Lindblom Christopher M |
See Remarks |
• – – |
2012-11-26 |
4 |
S |
$25.73 |
$357,272 |
D/D |
(13,885) |
0 |
|
- |
|
| Lindblom Christopher M |
See Remarks |
• – – |
2012-11-26 |
4 |
OE |
$9.80 |
$181,373 |
D/D |
13,885 |
13,885 |
|
- |
|
| Selby Norman C |
Director |
– • – |
2012-10-15 |
4 |
OE |
$8.87 |
$44,350 |
D/D |
5,000 |
5,000 |
|
- |
|
| Beacon Co |
10% Owner |
– – • |
2012-09-07 |
4 |
B |
$14.50 |
$78,540,193 |
I/I |
5,416,565 |
5,416,565 |
1.5 |
- |
|
| Rosebay Medical Co L.p. |
10% Owner |
– – • |
2012-09-07 |
4 |
B |
$14.50 |
$78,540,193 |
I/I |
5,416,565 |
5,416,565 |
1.5 |
- |
|
| Santabarbara Pedro |
Chief Medical Officer |
• – – |
2012-09-04 |
4 |
OE |
$6.50 |
$59,800 |
D/D |
9,200 |
9,200 |
|
- |
|
| Holtzman Steven H |
Director |
– • – |
2012-05-31 |
4 |
S |
$13.01 |
$749,025 |
D/D |
(57,573) |
0 |
|
- |
|
| Holtzman Steven H |
Director |
– • – |
2012-05-30 |
4 |
S |
$13.00 |
$142,454 |
D/D |
(10,958) |
57,573 |
|
- |
|
| Holtzman Steven H |
Director |
– • – |
2012-05-29 |
4 |
S |
$13.00 |
$2,460,939 |
D/D |
(189,303) |
68,531 |
|
- |
|
| Holtzman Steven H |
Director |
– • – |
2012-05-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
15,000 |
257,834 |
|
- |
|
| Perkins Adelene Q |
Pres & Chief Executive Officer |
• • – |
2010-12-16 |
4 |
B |
$6.00 |
$152,569 |
D/D |
25,000 |
316,538 |
2.81 |
- |
|
| Holtzman Steven H |
Exec Chair of the Board of Dir |
• • – |
2010-12-10 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
275,535 |
|
- |
|
| Perkins Adelene Q |
Pres & Chief Executive Officer |
• • – |
2010-08-25 |
4 |
B |
$4.99 |
$26,692 |
D/D |
5,349 |
291,538 |
2.81 |
- |
|
| Perkins Adelene Q |
Pres & Chief Executive Officer |
• • – |
2010-08-24 |
4 |
B |
$4.89 |
$218,343 |
D/D |
44,651 |
286,189 |
2.81 |
- |
|
| Palombella Vito J. |
Chief Scientific OfficerOffice |
• – – |
2010-05-18 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
4,117 |
|
- |
|
| Palombella Vito J. |
Chief Scientific OfficerOffice |
• – – |
2010-05-18 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
1,047 |
|
- |
|
| Palombella Vito J. |
Chief Scientific OfficerOffice |
• – – |
2010-05-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,117 |
|
- |
|
| Quirk Gerald E |
VP,Cor. Affairs & Gnrl Counsel |
• – – |
2010-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,680 |
|
- |
|
| Tong Jeffrey K |
VP, Cor. & Product Development |
• – – |
2010-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
17,246 |
|
- |
|
| Lee Patrick Pak-Tin |
Director |
– • – |
2009-02-19 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,123,756) |
0 |
|
- |
|
| Rosebay Medical Co L.p. |
10% Owner |
– – • |
2009-01-07 |
4 |
B |
$15.00 |
$15,000,000 |
D/D |
1,000,000 |
3,000,000 |
2.45 |
- |
|
| Beacon Co |
10% Owner |
– – • |
2009-01-07 |
4 |
B |
$15.00 |
$15,000,000 |
D/D |
1,000,000 |
3,000,000 |
2.45 |
- |
|
| Perkins Adelene Q |
Pres & Chief Business Officer |
• – – |
2008-12-17 |
4 |
B |
$7.88 |
$67,535 |
D/D |
8,500 |
241,538 |
2.74 |
- |
|
227 Records found
|
|
Page 6 of 10 |
|
|
